314
Participants
Start Date
August 1, 2014
Primary Completion Date
November 3, 2016
Study Completion Date
November 3, 2016
omalizumab
150mg omalizumab via sub-cutaneous injection once every 4 weeks
omalizumab
300mg omalizumab via sub-cutaneous injection once every 4 weeks
Novartis Investigative Site, Pilar
Novartis Investigative Site, Tlalpan
Novartis Investigative Site, Zapopan
Novartis Investigative Site, Santiago
Novartis Investigative Site, Santiago
Novartis Investigative Site, Santa Fe
Novartis Investigative Site, Rosario
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Salta
Novartis Investigative Site, Salvador
Novartis Investigative Site, Rio de Janeiro
Novartis Investigative Site, Alphaville / Barueri
Novartis Investigative Site, Santo André
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Vancouver
Novartis Investigative Site, St. John's
Novartis Investigative Site, St. John's
Novartis Investigative Site, Halifax
Novartis Investigative Site, Barrie
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Kingston
Novartis Investigative Site, Markham
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Peterborough
Novartis Investigative Site, Toronto
Novartis Investigative Site, Toronto
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Windsor
Novartis Investigative Site, Québec
Novartis Investigative Site, Toronto
Novartis Investigative Site, Santo Domingo
Novartis Investigative Site, Panama City
Novartis Investigative Site, Guatemala City
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY